1e
19
1
49
2
2
18
1b
1d
18
2d
82
1d
2 29
1d
25
Pablo Tebas, MD
78
82
Professor of Medicine (Infectious Diseases) at the Hospital of the University of Pennsylvania
28
76
3
5f
Attending Physician, Hospital of the University of Pennsylvania
a3
Director & Principal Investigator, AIDS Clinical Trial Unit (ACTU) research site, University of Pennsylvania
7d
Investigator of the Vaccine Trials Network, University of Pennsylvania
11
Department: Medicine
4
1
b
1d
46
Contact information
54
4
3
3
1d
54
Academic Address: 502 Johnson Pavilion
78 Clinical Office: 4 Perelman Center for Advanced Medicine, 3600 Civic Center Boulevard
Philadelphia, PA 19104
26
78 Clinical Office: 4 Perelman Center for Advanced Medicine, 3600 Civic Center Boulevard
Philadelphia, PA 19104
2e
Office: 215-349-8092
32 Fax: 215-349-8011
24
a5
12
32 Fax: 215-349-8011
24
18
Publications
23 a
3
2
29
23 a
Links
74 Search PubMed for articles
d
4
b
1f
74 Search PubMed for articles
d
13
Education:
21 7 MD c
3f Universidad Autónoma de Madrid, Spain, 1985.
c
3
3
3
3
8d
Permanent link21 7 MD c
3f Universidad Autónoma de Madrid, Spain, 1985.
c
2 29
21
1e
1d
24
5e
68 I am the director and the PI of the AIDS clinical trial unit of the University of Pennsylvania.
39e I am one of the founding members of the HIV Reservoirs and Viral Eradication (Cure) Transformative Science Group (TSG) of the AIDS clinical trial group. In addition to my ACTG work, I am involved (as PI of the clinical project) in several early phase trials of new compounds developed in conjunction with the NIH in several IPCP grants, including a Phase I study evaluating the antiviral activity of aprepitant (an NK-1R antagonist that down-regulates the expression of CCR5), a phase I study evaluating the immunogenicity of a therapeutic DNA vaccine administered by intramuscular electroporation in collaboration with David Weiner and several gene therapy studies evaluating the therapeutic use of lentiviral vectors in the management of HIV infection (including the use of VIRxSYS 496 –antisense approach-, the first in humans Sangamo’s zinc finger nuclease for CCR5 edition, in collaboration with Dr. Carl June.
65
1a 29
27
Description of Research Expertise
ba My research interests center around the study of the complications of HIV and its treatment, and currently in the evaluation of strategies for the cure of HIV infection.68 I am the director and the PI of the AIDS clinical trial unit of the University of Pennsylvania.
39e I am one of the founding members of the HIV Reservoirs and Viral Eradication (Cure) Transformative Science Group (TSG) of the AIDS clinical trial group. In addition to my ACTG work, I am involved (as PI of the clinical project) in several early phase trials of new compounds developed in conjunction with the NIH in several IPCP grants, including a Phase I study evaluating the antiviral activity of aprepitant (an NK-1R antagonist that down-regulates the expression of CCR5), a phase I study evaluating the immunogenicity of a therapeutic DNA vaccine administered by intramuscular electroporation in collaboration with David Weiner and several gene therapy studies evaluating the therapeutic use of lentiviral vectors in the management of HIV infection (including the use of VIRxSYS 496 –antisense approach-, the first in humans Sangamo’s zinc finger nuclease for CCR5 edition, in collaboration with Dr. Carl June.
65
Description of Clinical Expertise
15e My clinical interest focus on the treatment of HIV infection and associated infections like hepatitis C. I have also a particular interest in the clinical manifestations and treatment of atypical mycobacterial infections. I also attend every year in the general infectious disease service of the hospital of University of Pennsylvania1a 29
23
1a1 Short W.R., Scott R.K., Zimmerman M., Baron J., Momplaisir F., Patel D., Joseph N., Pierre C., Clarke D., Knapp K.M., Pagkalinawan S., Tebas P.: LA CAB/RPV in Pregnancy: Bimonthly Dosing in the Setting of Predicted Reduced RPV Exposure. 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 792 February 2026.
1c4 Orkin C.M., Mngqibisa R., Velez J.D., Kumar P., Braun D., Carr A., Bloch M., Walmsley S., Tebas P., Calmy A.L., Fuszard M., Diamond T.L., Jackson B., Fox M.C., Kim J.: Switch to DOR/ISL (100/0.25 mg) QD From Oral ART: Week 96 Update From an Open-Label Phase III Study. 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 515 February 2026.
1c8 Vendrame E., Fichtenbaum C.J., Osiyemi O., Wiznia A., Gupta S., Brimhall D., Morse C., Slim J., Tebas P., Liu X., Zheng Y., Chakrabarti T., Cortese M., Workowski K., Kumar P.: Safety, PK, and Pharmacodynamics of Amtabafusp, a Bispecific T-Cell Engager, in People With HIV. 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 371 February 2026.
1ab Choudhary M.C., Choi Y., Aga E., Bosch R.J., Silva de Assis T., Landais E., Reeves J.D., Petropoulos C.J., Montefiori D., Caskey M., Bar K.J., Smiley S., Tebas P.: Stable HIV-1 Autologous and Heterologous Virus Neutralization on Suppressive ART. 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 301 February 2026.
1ac Tebas P., Patel A., Agnes J., Parzych E.M., Tsang C., Morales K., Fisher P.D., Francica J.R., Humeau L., Pallesen J., Leon P., Esser M., Smith T.R.F., Weiner D.B.: Sustained DNA-Encoded SARS-CoV-2 Antibody Expression and Safety Through 96 Weeks. 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 180 February 2026.
1dd Cha R., Serebryannyy L., Sieczkarski S., Rupert C., Smith N.M., Venuto C.S., Ma Q., Morse G.D., Maenza J., Wagner Cardoso S., Tebas P., Mellors J.W., Belaunzaran Zamudio P., Arduino R.C., Crowell T.A.: Optimization of Dose and Analytic Treatment Interruption for VRC07-523LS and PGT121.414.LS. 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 491 February 2026.
181 DeStefanis T., Belinky F., Ko S.H., Coates E., Strom L., Happe M., Bar K.J., Tebas P., Boritz E., Lynch R.: In Vivo Escape Pathways to VRC07-523LS and VRC01LS and Their Effects on CD4bs bNAb Susceptibility. 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 578 February 2026.
143 Short W.R., Wessolossky M., Scott R.K., Zimmerman M., Tebas P.: Evaluating Viral Decay Kinetics of Long-Acting Cabotegravir/Rilpivirine in Pregnancy. 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 791 February 2026.
25d Tebas, P., Jadlowsky, J. K., Zhou, Y., Pampena, M. B., Leslie, G. J., Liu, N., Srivatsa, S., Maldini, C. R., Wang, J., Tsang, C. J., Mohamed, O., Romano, J., Haggarty, B., Plesa, G., Gaymon, A. L., Brennan, A. L., Veloso, E., Levine, B. L., Putt, M. E., Kulikovskaya, I., Gonzalez, V., Fraietta, J. A., Betts, M. R., Hoxie, J. A., Riley, J. L.: Clinical trial results provide the rationale to protect dual HIV-specific T cells with a signaling-defective HIV fusion inhibitor. Mol Ther 34(3): 1352-1366, 2026.
2c
7
1d
1f
Selected Publications
268 Orkin, C., Mngqibisa, R., Velez, J. D., Kumar, P., Braun, D. L., Carr, A., Bloch, M., Walmsley, S., Tebas, P., Yokomaku, Y., Diamond, T. L., Jackson, B., Eves, K., Grandhi, A., Fuszard, M., Klopfer, S. O., Stamm, L. M., Fox, M. C., Kim, J.: Switch to fixed-dose doravirine (100 mg) and islatravir (0.25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial. Lancet 407(10528): 599-610, March 2026.1a1 Short W.R., Scott R.K., Zimmerman M., Baron J., Momplaisir F., Patel D., Joseph N., Pierre C., Clarke D., Knapp K.M., Pagkalinawan S., Tebas P.: LA CAB/RPV in Pregnancy: Bimonthly Dosing in the Setting of Predicted Reduced RPV Exposure. 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 792 February 2026.
1c4 Orkin C.M., Mngqibisa R., Velez J.D., Kumar P., Braun D., Carr A., Bloch M., Walmsley S., Tebas P., Calmy A.L., Fuszard M., Diamond T.L., Jackson B., Fox M.C., Kim J.: Switch to DOR/ISL (100/0.25 mg) QD From Oral ART: Week 96 Update From an Open-Label Phase III Study. 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 515 February 2026.
1c8 Vendrame E., Fichtenbaum C.J., Osiyemi O., Wiznia A., Gupta S., Brimhall D., Morse C., Slim J., Tebas P., Liu X., Zheng Y., Chakrabarti T., Cortese M., Workowski K., Kumar P.: Safety, PK, and Pharmacodynamics of Amtabafusp, a Bispecific T-Cell Engager, in People With HIV. 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 371 February 2026.
1ab Choudhary M.C., Choi Y., Aga E., Bosch R.J., Silva de Assis T., Landais E., Reeves J.D., Petropoulos C.J., Montefiori D., Caskey M., Bar K.J., Smiley S., Tebas P.: Stable HIV-1 Autologous and Heterologous Virus Neutralization on Suppressive ART. 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 301 February 2026.
1ac Tebas P., Patel A., Agnes J., Parzych E.M., Tsang C., Morales K., Fisher P.D., Francica J.R., Humeau L., Pallesen J., Leon P., Esser M., Smith T.R.F., Weiner D.B.: Sustained DNA-Encoded SARS-CoV-2 Antibody Expression and Safety Through 96 Weeks. 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 180 February 2026.
1dd Cha R., Serebryannyy L., Sieczkarski S., Rupert C., Smith N.M., Venuto C.S., Ma Q., Morse G.D., Maenza J., Wagner Cardoso S., Tebas P., Mellors J.W., Belaunzaran Zamudio P., Arduino R.C., Crowell T.A.: Optimization of Dose and Analytic Treatment Interruption for VRC07-523LS and PGT121.414.LS. 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 491 February 2026.
181 DeStefanis T., Belinky F., Ko S.H., Coates E., Strom L., Happe M., Bar K.J., Tebas P., Boritz E., Lynch R.: In Vivo Escape Pathways to VRC07-523LS and VRC01LS and Their Effects on CD4bs bNAb Susceptibility. 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 578 February 2026.
143 Short W.R., Wessolossky M., Scott R.K., Zimmerman M., Tebas P.: Evaluating Viral Decay Kinetics of Long-Acting Cabotegravir/Rilpivirine in Pregnancy. 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 791 February 2026.
25d Tebas, P., Jadlowsky, J. K., Zhou, Y., Pampena, M. B., Leslie, G. J., Liu, N., Srivatsa, S., Maldini, C. R., Wang, J., Tsang, C. J., Mohamed, O., Romano, J., Haggarty, B., Plesa, G., Gaymon, A. L., Brennan, A. L., Veloso, E., Levine, B. L., Putt, M. E., Kulikovskaya, I., Gonzalez, V., Fraietta, J. A., Betts, M. R., Hoxie, J. A., Riley, J. L.: Clinical trial results provide the rationale to protect dual HIV-specific T cells with a signaling-defective HIV fusion inhibitor. Mol Ther 34(3): 1352-1366, 2026.
2c